Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra System or with a standard cardiopulmonary bypass

被引:114
作者
Remadi, JP
Rakotoarivelo, Z
Marticho, P
Benamar, A
机构
[1] South Hosp, Cardiac Surg Unit, F-80054 Amiens 1, France
[2] South Hosp, Anesthesiol Unit, F-80054 Amiens 1, France
关键词
D O I
10.1016/j.ahj.2005.03.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background To assess the potential benefits of a new concept of cardiopulmonary bypass (CPB), the mini-extracorporeal circulation (MECC) Jostra System, we conducted a prospective randomized study among patients who underwent coronary artery bypass grafting (CABG) with a MECC Jostra System or with a standard CPB. Methods In a prospective randomized study, 400 patients underwent elective CABG using a standard CPB (200 patients) or a Jostra MECC System (200 patients). The patients were randomly assigned to have preoperative data similar for both groups. Results The operative mortality rate (<30 days) was 1.5% for the MECC group and 2.5% for the CPB group (P = NS). Low-cardiac-output syndrome occurred in 0.66% and 4% for the CPB group (P <.001.). The inflammatory response was significantly reduced with the MECC. Likewise, C-reactive protein release was significantly higher in group B at 24 hours (69.6 +/- 38.5 vs 40.8 +/- 21.8 mg/L for the group A, P<.01) and at 48 hours (116.7 +/- 47.0 vs 65.4 +/- 39.5 mg/L, P<.05) postoperatively, In the CPB group, there was a significantly higher decrease of hematocrit and hemoglobin rate. So, the intraoperative transfusion rate amounted to 6% for the MECC group and 12.8% for the CPB group (P<.001). Patients in the CPB group had significantly higher levels of postoperative blood creatinine and urea. Conclusion The MECC system is a new concept of CPB that seems to be reliable and safe. To perform CABG, the MECC provides an excellent surgical exposure like a standard CPB and a better biologic profile like CABG without CPB.
引用
收藏
页码:198.e1 / 198.e7
页数:13
相关论文
共 21 条
[1]  
Alamanni F, 2001, J Extra Corpor Technol, V33, P4
[2]   INFLAMMATORY RESPONSE TO CARDIOPULMONARY BYPASS [J].
BUTLER, J ;
ROCKER, GM ;
WESTABY, S .
ANNALS OF THORACIC SURGERY, 1993, 55 (02) :552-559
[3]   Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting [J].
DeFoe, GR ;
Ross, CS ;
Olmstead, EM ;
Surgenor, SD ;
Fillinger, MP ;
Groom, RC ;
Forest, RJ ;
Pieroni, JW ;
Warren, CS ;
Bogosian, ME ;
Krumholz, CF ;
Clark, C ;
Clough, RA ;
Weldner, PW ;
Lahey, SJ ;
Leavitt, BJ ;
Marrin, CAS ;
Charlesworth, DC ;
Marshall, P ;
O'Connor, GT .
ANNALS OF THORACIC SURGERY, 2001, 71 (03) :769-776
[4]   Renal effects of cardiopulmonary bypass in the elderly [J].
Dehne, MG ;
Sablotzki, A ;
Mühling, J ;
Dehne, KL ;
Röhrig, R ;
Hempelmann, G .
PERFUSION-UK, 2002, 17 (03) :205-209
[5]  
Farsak B, 2002, HEART SURG FORUM, V5, P358
[6]   Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation [J].
Fromes, Y ;
Gaillard, D ;
Ponzio, O ;
Chauffert, M ;
Gerhardt, MF ;
Deleuze, P ;
Bical, OM .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 22 (04) :527-533
[7]   Adsorption of inflammatory cytokines using a heparin-coated extracorporeal circuit [J].
Fujita, M ;
Ishihara, M ;
Ono, K ;
Hattori, H ;
Kurita, A ;
Shimizu, M ;
Mitsumaru, A ;
Segawa, D ;
Hinokiyama, K ;
Kusama, Y ;
Kikuchi, M ;
Maehara, T .
ARTIFICIAL ORGANS, 2002, 26 (12) :1020-1025
[8]  
Gibbon J.H., 1953, Recent Advances in Cardiovascular Physiology and Surgery Minneapolis, P107
[9]   Heparin-coated cardiopulmonary bypass circuits: current status [J].
Hsu, LC .
PERFUSION-UK, 2001, 16 (05) :417-428
[10]   Hemostatic activation and inflammatory response during cardiopulmonary bypass - Impact of heparin management [J].
Koster, A ;
Fischer, T ;
Praus, M ;
Haberzettl, H ;
Kuebler, WM ;
Hetzer, R ;
Kuppe, H .
ANESTHESIOLOGY, 2002, 97 (04) :837-841